天演药业 ADAG 深 沪
已收盘 10-16 16:00:00 美东时间
2.06
-0.340
-14.17%
华盛通- 最 高2.40
- 今 开2.40
- 成交量 37.96万股
- 最 低 2.01
- 昨 收 2.40
- 总市值 1.38亿
- 52周最高 4.85
- 市盈率 静 --
- 换手率 0.57%
- 52周最低 1.30
- 委 比 -56.78%
- 总股本 6714.33万
- 历史最高 31.83
- 量 比 0.54
- 振 幅 16.25%
- 历史最低 0.90
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多天演药业收跌14.17%，成交额83.7万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
今天 06:56
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Adagene Inc. announced that its CEO and R&D President, Peter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference on October 15, 2026. Adagene is a clinical-stage biotech company leveraging computational biology and AI to develop innovative antibody-based cancer immunotherapies. Its proprietary SAFEbody technology aims to enhance safety and efficacy by targeting tumors while mini...
10-14 12:00
Adagene Announces Finance Executive Resignation Effective September 30, 2026
The latest announcement is out from Adagene ( ($ADAG) ). On September 30, 2026,...
09-26 05:01
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective t...
09-22 20:01
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Adagene's ADG138, a double-masked HER2×CD3 bispecific T-cell engager using the company's SAFEbody® technology, has received IND approval from China's NMPA. The Phase 1 study for advanced solid tumors is set to begin in Q4 2026. Preclinical data shows strong tumor regression in Enhertu-resistant models and synergy with other immunotherapies, with reduced toxicity and improved safety profile.
09-22 12:00
9月18日美股收盘：三大股指收涨 科技股推动大盘走高 油价下跌同样提振股市
美国股市周四上涨，受美国国债收益率和油价回落以及关键科技股走强支撑，交易员收复了前一交易日的失地，并摆脱了美联储三年来首次加息后的不安情绪。此前，美联储加息...
09-18 04:16
纳斯达克中国金龙指数涨超0.5%，爱奇艺涨7.87%
每经AI快讯，9月17日，纳斯达克中国金龙指数涨超0.5%，爱奇艺涨7.87%，燃石医学涨6.95%，天演药业涨6.15%，知乎涨5.35%，再鼎医药涨5.1...
09-17 23:48
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
